Wednesday, August 21, 2013

Bechdel and Mako Mori

People criticise the Bechdel Test because they think it's either a poor benchmark for film quality or because they think it's the final word on women in film. Either case is incorrect; ultimately I think it probably best serves both as an agent provocateur to discussion about representations of women in media and as a reminder to think critically about the media we digest.

At any rate, looks like Pacific Rim (I didn't get around to seeing it) inspired a new test. Feel free to discuss.

'The Mako Mori Test: 'Pacific Rim' inspires a Bechdel Test alternative' at The Daily Dot (via bitchmedia)

Tuesday, August 20, 2013

The one about the free-for-all over price disclosure

So, the Consumers Health Forum (CHF), CHOICE and the Australian Council of Social Service (ACOSS) just stepped up their game in this fight brewing over early price disclosure, issuing a joint media release urging consumers not to sign the petition butohwait here's our petition, and let's tell those pollies we won't stand up to Pharmacy Guild bullying over the cost of our medicines!

Predictably the Guild issued their response, keeping to the same language and points they've kept throughout the 'Under Threat' campaign. Oh, they made some concessions to new points the former brought up, with their retort that pharmaceutical spending as % of GDP is relatively low and falling; claims I really don't want to look into (because I'm sure the Guild wouldn't fudge those numbers; certainly not because it's GDP, which means economics, which means boring).

For the most part though, there's some stuff in the CHF/CHOICE/ACOSS media release that's ripe for investigation. Australian consumers and taxpayers paying ten times the British price for prescriptions?

I don't have time to join the dots, but I'll provide the links for anyone who's interested. If you're going to have a look at them, here are some possible questions to consider:

  • How much do consumers pay for a single subsidised prescription in the UK or NZ relative to here?
  • How much does the government pay for covering the cost of a subsidised prescription in the UK or NZ relative to here?
  • How much do pharmacies make off a single prescription?
  • If pharmacies make so little money off prescriptions in the UK or NZ, how does that affect their viability? Do they provide others services? Are those subsidised by the government as well? What kind of relationship exists between community pharmacy and the patient in those countries? Is community pharmacy over there structured substantially different than to here?


Pharmaceutical Benefits Scheme - The Australian system that subsidises the cost of medicines. Explanatory notes here and a list of the fees and how the PBS is applied using examples here.

The Pharmaceutical Management Agency (PHARMAC) - New Zealand's organisation that is responsible for their version of the PBS, the New Zealand Pharmaceutical Schedule

Ministry of Health New Zealand - Prescription Charges - Information on the cost of subsidised medicines in NZ to the consumer.

National Health Service (NHS) - Help with Prescription Costs - The NHS is responsible for all subsidised healthcare in the UK (sort of; from what I can tell, there are slightly different bodies between England, Wales, Scotland and Northern Ireland, but whatever). This provides information on the cost of subsidised medicines in England to the consumer.

Unfortunately I can't seem to find information on the cost of individual medicines to the consumer and to the government for the UK; they don't appear to have anything like PBS or the PHARMAC's Pharmaceutical Schedule accessible online. Of course that doesn't mean they don't; maybe I simply haven't looked hard enough. If there is something, I'm betting it'll be somewhere in the NHS Business Services Authority's website for prescription services. If you find it I'd love to know.

Now for some coverage on the issue from other areas:

'Australia's Bad Drug Deal - High pharmaceutical prices' - A report by Stephen Druckett for the Grattan Institute. Compares what the government pay for subsidised medicines here relative to other countries. Pages 31 and 32 are most relevant, but it's a pretty interesting read overall. Published in March earlier this year.

'Pharmacy gravy train drives up the cost of prescription drugs' - Article by Rollo Manning for The Conversation. Came out around the same time as the Grattan Institute report.


Monday, August 19, 2013

The long one about accessing journals

In fourth year we've been encouraged to subscribe to a range of academic journals; after all, it's important to keep up with the latest information not only to optimise patient outcomes, but also to 'broaden your horizons' about practices lateral to ours, and about the current state of healthcare in general (although looking smart in front of potential employers for your intern year by being able to refer to this-or-that latest review may have its benefits as well).

Inevitably this is easier said than done. For starters, while the five or so journals recommended within the subjects are important and relevant it isn't enough, considering how wide a scope we need to be knowledgeable about. Also, half of them require a library subscription, which may be all well and good now we're still at uni, but what happens after we graduate? Some of the National Intern Training Programs provide access to journals but after your intern year unless you work for an organisation that pays for access (most community pharmacists don't) you're stuck. Speaking of library journal access, setting up email alerts for new journal issues can be a trial, and often when they're sent you're unable to access the articles directly from the email (you have to access them manually via the library website).

Also, what are the good resources to subscribe to? There are an awful lot out there and as a time-starved pharmacy student (or early career pharmacist) you really want to screen for those that are both high quality and most relevant to your learning goals. X journal might be the world leader in applied x-ray crystallography for pharmacology, but I suspect unless you're in the field you're gonna have a bad time.

Let's begin with identifying the popular journals. "Popular?", you say, "But I wanted high quality." Well, sadly it isn't that simple, as my project partner and I discovered to our dismay over the last month while researching ways to evaluate sources of information for an assignment. Have you ever had anyone recommend using Impact Factor as a way to evaluate whether something is good quality? It isn't; in fact, about the only things it's validated for are 'informing citation patterns and guiding library purchasing decisions' (Vanclay, 2012, p. 212).

No, Impact Factor, Eigenfactor and all the other quantitative bibliometrics (as they're called): They can't confirm for you the quality of a journal, and they certainly can't confirm for you the quality of an individual paper published by that journal (sorry, but you're going to have to do some actual thinking at some point- I know, I know). They *can* tell you something about the popularity of a journal though; essentially, what everybody else is reading. At this point in your career, I'd reckon that's a pretty good start.

Anyway, if you want to look at the most popular journals I'd recommend Eigenfactor, partially because it's arguably more accurate than using Journal Citation Reports (aka Impact Factor), but more importantly it's free to access. Go down to 'Search by ISI Category' and pick your field; for me at this point that's 'Medicine - General and Internal' and 'Pharmacology and Toxicology'.

It'll then rank the journals by their Eigenfactor. Oh, other cool thing: The Eigenfactor website will also plot the price and cost effectiveness of each journal, which makes it easy to find journals that are free or open access, like the Cochrane Database of Systematic Reviews below:





Yay for free or open access journals! Some require you to make a free account and others don't but generally speaking these journals don't charge to view papers they publish. Doesn't mean they're all good but hey, now you can find journals that are both free and popular!

I suppose I should get to a point of recommending a few I found through here and elsewhere. I'll begin with the ones you don't have to pay for:

  • NPS Medicinewise - If you're in fourth year of pharmacy you'd be more than familiar with the NPS already, and you probably have your free subscription to Australian Prescriber, but did you know you can subscribe to all their other periodicals? 'Subscribe for free' on the right hand side to NPS RADAR (evidence-based reviews of new medications and indication changes to medications previously listed on PBS) and Medicinewise News (reviews of other medical issues). They also provide NPS Pharmacy Practice Reviews which qualify for Group 2 CPD points.
  • The Cochrane Library - Provides the Cochrane Database of Systematic Reviews. This is your one-stop-shop for (arguably) the best in meta-analyses and systematic reviews; one of the pillars of evidence-based medicine. Oh! They also provide the Cochrane Journal Club; each issue deals with one paper, they give you the background to the research, provide discussion points in order to teach you to evaluate journal papers qualitatively, and give you links to related resources.
(As an interesting tidbit, the Cochrane Collaboration logo is a stylised example of a forest plot and represents the evidence, viewed systematically for using corticosteroids to reduce mortality in prematurely born infants. Unfortunately while there was evidence of benefit as early as 1972, obstetricians were sceptical for a number of reasons (see the section on systematic reviews in Trisha Greenhalgh's awesome How to Read a Paper for more info on why), and it wasn't until 1989 that the first systematic review was published on that topic. If the technique had been available earlier, well, you can see what I'm getting at. Point is, when it comes to evaluating the evidence for something, as humans we need to be aware of our own fallibility; we can place too much weight on evidence gained during the here and now, with our own senses, drowning out the subtle and the gradual.

Ahem. That was quite a tangent; back to it.)


  • PLoS Medicine - The Public Library of Science (PLoS) are an American non-profit organisation that publish a range of open-access journals, PLoS Medicine being one. It provides quite a broad range of papers; I actually referenced an article from here in my last blog entry.
  • BMC Medicine and BMC Pharmacology and Toxicology - BioMed Central (BMC) are the UK equivalent of PLoS, and are older too. These two journals are the most important, I think, but they do a large range of other journals too (e.g. Cancer, Cardiovascular, Nephrology, and more); the full list is here.
  • BMJ Open - An open-access journal published by the BMJ Publishing Group (who as you may have guessed, publish the British Medical Journal).

The next couple I've only recently found, but are also open-access or free, so take a look around:

Just a quick observation I've made; the student journals appear to have a decent mix of serious research articles and more lighter fare, like the gamification article mentioned above. Makes for more interesting reading.
  • Pharmacy Practice - I have no idea what this one is like, but it was recommended by one of the subject co-ordinators here. Just browsing now and it looks like they have some interesting articles.
I suppose I should finish by briefly mentioning the journals that generally aren't free, but are nonetheless important to the field. Sometimes you get lucky with a free article, but more often than not you'll have to access these journals via a library or an organisation's subscription (e.g. CIAP if you work in the NSW hospital system, or Clinicians Health Channel in Victoria). In no particular order:



An important point for students: With many of the above even if you don't have access from home you can generally set up email alerts for free, so you're notified when a new issue comes out. As I said before, generally you can't access the articles in the alert directly from the email (everything has to flow through the library or organisation's access), but at least with them set up you can browse the table of contents for articles you want to read, then open up the library webpage and access them through there.

Well, I think that's about enough written for one day. If I've made any mistakes, or if you've got another journal or other resource you'd recommend, I'd love to know so drop a line and comment.



Vanclay, J. K. (2012). Impact factor: Outdated artefact or stepping-stone to journal certification? Scientometrics, 92(2), 211-238. doi: 10. 1007/s11948-010-9212-8

Saturday, August 17, 2013

Falsely charged: Sue Dunlevy versus the Pharmacy Guild of Australia

Now, I said I was going to bring up an issue I've had with the Pharmacy Guild recently and I will, but by way of an article published recently in News Corp Australia papers, "Patients miss out on prescription medicines price cut" (Dunlevy, 2013).

That's right: I reference using APA6. In blogs. I'm cool.

Anyway, Sue Dunlevy (the author) has copped a bit of flak over the article from the Guild and pharmacists who've alleged she's misrepresented the profession and brought it into disrepute. The Guild have called the article "plain wrong", while others have noted the author seems to be involved with every bad pharmacy news story published by News Corp Australia. To be fair, she is a health reporter; if there's anyone at News Corp Australia who's going to report on a health-related issue, it'd be her, which is why her name comes up frequently.

Look, I think there's a couple of things she could've done to improve the article. For instance, it would've been nice if the article clearly stated the $4.11 'allowable additional patient charge' was also capped by the general patient co-payment, or that it couldn't be applied to concession patients (Commonwealth of Australia, n.d.). It would've been more realistic if she gave the average percent over market price the Government pays rather than the 80 percent (though I wouldn't know what that average is). Probably the most important thing missing is evidence of whether pharmacies are actually applying this charge and if so, how many, where and to what medicines.

Having said all that though, I've read the thing maybe half a dozen times now, and while I initially got that feeling she was trashing the reputation of the profession, I don't see it now and I think I was wrong when I reacted to the article that way initially.

Excusing the points I made above, everything else in that article seems legitimate. Yes, there is an allowable additional patient charge, capped at $4.11 that can be applied at the pharmacy's discretion to medicines priced beneath the general co-payment. If charged, it doesn't count towards the patient's Safety Net threshold. Yes, it could be used to offset or 'top up' the cost of a medicine if it falls beneath $36.10 and yes, there's plenty of evidence to show that the cost of a medication can affect patient adherence (Ortiz, 2013). Given that evidence, it's unsurprising that Rollo Manning, CHF chief Carol Bennett and Professor Phillip Clarke express concern. The Guild weren't robbed of right of reply; the article gives a Guild spokesperson the opportunity to ground this patient charge in the everyday reality of community pharmacy.

I think the response I'm seeing to this article from pharmacists says more about the frustration they feel, considering many in the professional are genuinely doing the best they can to improve patient outcomes. Community pharmacy is stuck between the figurative rock and a hard place on this, because pharmacists know and see patients holding off from getting scripts filled for cost reasons, but in order to provide a professional service, pharmacies have to remain financially viable.

This is the argument that needs to be presented to the community; that it isn't just about cost to the consumer, and that compromising pharmacy financially can have far-reaching effects on health outcomes, beyond affordability. The recent actions by the Guild and releases from the PSA and NAPSA have taken the right approach on this I think with respect to the price disclosure issue.

Of course, it could also be the timing of the article (right in the middle of the campaign against the advancement of price disclosure), which is unfortunate. Still, she wrote it and it's released now, so if pharmacy is going to have a discussion with the community about this $4.11 charge, we should be talking about why it's in there, why pharmacies have it to use at their discretion (even if they aren't using it). and what we can all do about finding a way to work around having to use it or need it in future.

This is where I can't trust the Guild; I think they have it totally wrong in their reply by media release (Pharmacy Guild of Australia, 2013), by 'straw manning' her argument, suggesting she was saying pharmacies can use the charge above the general co-payment, which she never said. Furthermore they focus on the 'secret' part and forget the part where she says 'chemists are required to tell patients when they impose the $4.11 charge and the fact it is not initiated by the government'. Most frustrating of all, the media release doesn't attempt to grapple at all with the truths in the article, calling it 'plain wrong'. I tried querying the Guild on this via their Facebook page, and the reply I got again falsely accused the article of saying the charge could be used above the co-payment. I'll quote directly from the article: "...chemists can top up the cost of medicines that fall below a $36.10 co-payment figure...". That's "above", not "below". The two words don't even look similar.

Hmph. It seems to me if they're going to accuse someone of being 'deliberately misleading', they could probably do with a look in the mirror. 

Am I wrong? Do I think too highly of the comprehension skills of the Guild's media team? I mean, how likely do you think it is they responded to the article in that way because it was misread? I don't think that's likely, and as a result I can't help but think the media release is a deliberate attempt to obfuscate the issue, either generating sympathy for pharmacy or stirring the pot to energise the base for the 'Under Threat' campaign.

Feel free to correct me if I've got facts wrong or made an error in interpretation, or used poor assumptions.


References (though I wonder what's the point where I learnt to hyperlink text through the article) (Is it cheating to reference paper journals like Australian Prescriber more simply by referencing them as websites where applicable?)

Commonwealth of Australia. (n.d.) Fees, Patient Contributions and Safety Net Thresholds - History of PBS Copayments and Safety Net Thresholds. Retrieved 16/08/2013, from http://www.pbs.gov.au/info/healthpro/explanatory-notes/front/fee

Dunlevy, S. (2013). Patients miss out on prescription medicines price cut. Retrieved 16/08/2013, from http://www.news.com.au/lifestyle/health-fitness/patients-miss-out-on-prescription-medicines-price-cut/story-fneuz9ev-1226696601576

Ortiz, M. (2013). Are prescription copayments compromising patient care? Retrieved 16/08/2013, from http://www.australianprescriber.com/magazine/36/1/2/3

The Pharmacy Guild of Australia. (2013). Media Release - Media reports on medicine pricing just plain wrong. Retrieved 16/08/13, from http://www.guild.org.au/news-page/2013/08/14/media-release---media-reports-on-medicine-pricing-just-plain-wrong

Your local pharmacy: Under threat?

To all my people not affiliated with pharmacy in some way,

If you've been into a community pharmacy any time in the past week or if you follow the news you might've heard the Government has accelerated price disclosure for Pharmaceutical Benefits Scheme-subsidised medicines from every 18 months to every 12 months. Basically this means the price of medicines can drop; some more than others. Patients may save up to a couple of dollars on a script (though this really only applies to people without concession), and the Government pays less for the medicines it subsidises, potentially allowing new drugs to be subsidised without blowing the budget. 

Nobody's disputing the importance of all the above; being able to list new drugs can allow people access to new treatments for say, Multiple Sclerosis, while increasing the affordability of medicines reduces the likelihood of someone skipping their medicine because they can't afford it this week. As it is, we've been performing price disclosure for a number of years now. Of course, if less money is changing hands, it means there's less money that ends up in community pharmacies, and while it has been tricky for some pharmacies and owners on a whole it's been dealt with well, not least due to negotiations like the Fifth Community Pharmacy Agreement. Basically that's an agreement between the Pharmacy Guild (who represents community pharmacy owners) and the Government where community pharmacies agree to provide certain services, and in exchange the Government will pay for or subsidise the cost of those services.

The problem with this current round of price disclosure is that it's six months earlier than expected, and according to the Pharmacy Guild nobody was consulted. That kind of consultation is important because it gives community pharmacy an opportunity to present its case on how price disclosure will affect the financial viability of pharmacy, and to negotiate for ways community pharmacy can earn that money via another route (e.g. providing a cheap/free Webster pack service for their elderly customers).

As a result, between the last price disclosure and this new one (occurring in October) the Guild reckons the average pharmacy will have $90,000 wiped off their bottom line. To put that in perspective, that's a full time pharmacist plus a part time pharmacy assistant. It means pharmacies are likely going to have to scale back on services not subsidised by Government. It affected the viability of smaller pharmacies, particularly those in rural and regional areas. To quote from a Guild spokesperson, "there are 410 towns in which there is only one pharmacy, and our analysis indicates that 150 of those 410 pharmacies may be unviable next financial year". 

I don't always trust the Guild (I'll post a recent example after this; after all, they're conflicted by having to represent both community pharmacy and the interests of pharmacy owners who have financial as well as ethical concerns), but even if the numbers don't turn out as badly as they suggest, why wouldn't the Government consult on this? At best, it strikes me as an opportunity to do some good that hasn't been thought out as well as it should be given the potentially far-reaching effects. At worst? It's a political play, and given the timing it would make sense. I don't know.

There's a petition that's been organised. Make up your own mind; do some reading on the topic. If you need more information or just someone to point you in the right direction, let me know. If you are concerned about it though, I have a link to the online petition here: https://www.change.org/en-AU/petitions/australian-government-to-save-local-pharmacies-jobs-and-patient-services# . Alternatively your local community pharmacy is likely to have a paper one either at the register or where you hand in your prescriptions.

Wow. This is a lot longer than I intended it to be. Need to work on shorter statements.

Eww, old posts

What do I do with them though? I find old writing embarrassing (especially old writing written for the purpose of making that sweet sweet student magazine money, all $15 of it) but I'd feel dishonest taking them down. Would someone like to phone in with a suggestion?